Meeting
2017 ASCO Annual Meeting
Chemotherapy-induced ovarian failure (CIOF) in young women with early breast cancer (EBC).
Authors
Jenny Furlanetto
German Breast Group (GBG), Neu-Isenburg, Germany
Jenny Furlanetto , Christian Thode , Martina Bassy , Carsten Denkert , Claus Hanusch , Jens Bodo Huober , Christian Jackisch , Sherko Kummel , Andreas Schneeweiss , Michael Untch , Peter A. Fasching , Thomas Karn , Frederic Marme , Marion van Mackelenbergh , Volkmar Müller , Christian Schem , Gunter Von Minckwitz , Dominika Strik , Valentina Nekljudova , Sibylle Loibl
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Patient and Survivor Care
Track
Patient and Survivor Care
Sub Track
Survivorship
Citation
J Clin Oncol 35, 2017 (suppl; abstr 10068)
DOI
10.1200/JCO.2017.35.15_suppl.10068
Abstract #
10068
Poster Bd #
57
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
GAIN-2: Neo-/adjuvant phase III trial to compare intense dose-dense chemotherapy (CT) to tailored dose-dense CT in patients (pts) with high risk early breast cancer (EBC): Results on safety and interim invasive disease-free survival (iDFS).
First Author: Volker Moebus
Poster
2013 ASCO Annual Meeting
Adjuvant phase III trial to compare intense dose-dense adjuvant treatment with EnPC to dose dense, tailored therapy with dtEC-dtD for patients with high-risk early breast cancer (GAIN-2).
First Author: Volker Moebus
Poster
2012 Breast Cancer Symposium
Adjuvant chemotherapy for early-stage breast cancer: Choice of regimen and associated hematologic toxicities in a metropolitan Australian hospital.
First Author: Katherine Lovat
Poster
2021 ASCO Quality Care Symposium
Association of primary prophylactic (PP) granulocyte-colony stimulating factor (G-CSF) use with chemotherapy dose modifications and relative dose intensity (RDI) among breast cancer patients receiving high-risk regimens for febrile neutropenia (FN).
First Author: Jaime Shaw